The world is facing an unprecedented increase in type 2 diabetes. Most disability and premature mortality experienced by patients with diabetes is related to vascular disease and, in particular, macrovascular disease (such as coronary heart disease and stroke) and microvascular disease (such as retinopathy, nephropathy and neuropathy). Indeed, around 1.9 million cardiovascular deaths worldwide are attributable to high blood glucose levels and diabetes, as well as to their associated dangerous companions of high blood pressure and abnormal lipid levels. The global economic costs of diabetes, including foregone economic growth and increasing healthcare expenditure, are substantial and are anticipated to grow. Therefore, strategies to reduce disease burden have continued to focus on reducing cardiovascular risk. Recently, a number of large-scale clinical trials have evaluated approaches for managing cardiovascular risk in patients with type 2 diabetes. Among them the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN MR Controlled Evaluation (ADVANCE) trial has reported the effects of blood pressure lowering and intensive glucose control on major vascular events in patients with established type 2 diabetes. In this article we summarise the findings of the ADVANCE trial and discuss its relevance to the management of cardiovascular risk in patients with type 2 diabetes worldwide.
Summary of the ADVANCE Trial Findings
The ADVANCE trial was a factorial, randomised study of 11, 140 individuals with type 2 diabetes from over 200 collaborating centres in 20 countries from Asia, Australasia, Europe and North America.
Participants with either a history of macrovascular or microvascular disease or at least one major risk factor for cardiovascular disease and any initial level of blood pressure (BP) and blood glucose were randomly assigned to the fixed combination of the angiotensinconverting enzyme (ACE) inhibitor perindopril and the thiazide diuretic indapamide (4/1.25mg) or matching placebo and to intensive glucose control or standard guideline-based glucose control.
1,2 The glucose-lowering regimen for those randomised to intensive glucose control was based on the modified-release sulphonylurea gliclazide-MR 30-120mg daily. However, nonpharmacological approaches, other oral agents and insulin were recommended to be added as required to achieve the target glycated haemoglobin (HbA 1c ) level of ≤6.5%. 2 The choice of additional treatments was left to the discretion of the responsible physician. Participants randomised to standard guidelines-based glucose control were permitted to use sulphonylureas (other than gliclazide) and any other available glucose-lowering therapy, including insulin. The primary outcomes were composites of major macrovascular (non-fatal acute myocardial infarction, non-fatal stroke and cardiovascular death) and major microvascular events (new or worsening nephropathy and microvascular eye disease), analysed jointly and separately. The average duration of follow-up was 4.3 years for the BP-lowering intervention and five years for the glucose control intervention. 1, 2 In the BP-lowering arm of the study, the mean entry BP of participants was 145/81mmHg, with over 40% recording a BP below 140/90mmHg. 1 Over the duration of active treatment, BP was reduced by a mean of 5.6/2.2mmHg compared with placebo. At the end of follow-up the mean BP achieved was 134.7/74.8mmHg in the active treatment group and 140.3/77.0mmHg in the placebo group (see Figure 1 ). 1 Active treatment reduced the risk of the combined composite primary outcome of macrovascular and microvascular events by 9% (95% confidence interval [CI] 0-17; p=0.043). The effects on major macrovascular events considered separately were of similar magnitude but not statistically significant (see Figure 2 ). evidence of heterogeneity in treatment effect in subgroups of participants defined by key baseline characteristics. In particular, the effects of the treatment were similar across a range of initial BP levels and regardless of use of concomitant therapies (including ACE inhibitors, statins and aspirin).
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In the glucose-lowering arm, the mean entry HbA 1c of participants was 7.5%, with 91% already receiving oral hypoglycaemic agents. 2 By the end of follow-up of those in the intensive control group and standard care group, respectively, 92 and 59% were receiving sulphonylurea, 74 and 67% metformin, 40 and 24% insulin and 17 and 11% thiazolidinediones. Intensive glucose control resulted in a mean HbA 1c of 6.5%, compared with 7.3% in the standard arm, to produce an average difference during follow-up of 0.7% between the groups (see Figure 3 ). 2 In addition, the target HbA 1c of 6.5% or less was achieved by 65% of those assigned intensive glucose control, compared with 29% of those assigned standard care. Intensive glucose control reduced the incidence of combined major macrovascular and microvascular events by 10% (95% CI 2-18; p=0.01). This was primarily due to a significant 21% reduction in the incidence of new or worsening nephropathy. There were no significant effects of intensive glucose control on major macrovascular events (relative risk reduction [RRR)]
6%, 95% CI -6 to 16; p=0.32) (see Figure 2 ), cardiovascular mortality (RRR 12%, 95% CI -4 to 26; p=0.12) or all-cause mortality (RRR 7%, 95%
CI -6 to 17; p=0.28). 2 The treatment effects were consistent across a range of participant subgroups defined by key baseline characteristics, including duration of diabetes and prior history of macrovascular or microvascular disease (p>0.1 for heterogeneity for all comparisons).
2
Safety and Tolerability of the ADVANCE Trial Interventions
The fixed combination of perindopril and indapamide was well tolerated. At the end of follow-up, 73 and 74% of patients in the active treatment and placebo groups, respectively, remained adherent to their randomised treatment. 1 Serious suspected adverse drug reactions leading to discontinuation were reported in 47 (0.8%) of patients on active treatment and 31 (0.6%) of patients on placebo. These included 14 cases of hyperkalaemia (six active, eight placebo), two cases of hypokalaemia (two active) and five cases of hyponatraemia (four active, one placebo). There were also five non-fatal cases of angioedema (three active, two placebo). 1 As expected, in the glucose control arm severe hypoglycaemia was more frequent with intensive glucose control (0.7 cases per 100 patient-years) than with standard care (0.4 cases per 100 patientyears). 2 However, the overall incidence of severe hypoglycaemia in ADVANCE was much less than that reported by other studies of more intensive glucose lowering. [3] [4] [5] In addition, there was no increase in mean bodyweight among patients randomised to intensive glucose control, but a small reduction in mean bodyweight among those allocated to standard glucose control, so the mean bodyweight of the participants in the intensive arm was 0.7kg higher than in the standard care arm at the end of follow-up (p<0.001). 2 No increase in death was observed with intensive glucose control compared with standard glucose control. greater risk of myocardial infarction and 37% greater risk of microvascular disease. 17 Tight glucose control in the UKPDS was also The results of the blood-glucose-lowering arm of the ADVANCE trial indicated that HbA 1c values at or below levels currently recommended by most guidelines could be safely achieved in patients with long-standing type 2 diabetes using the regimen employed in ADVANCE. 2 In the short term, this approach did not reduce the risks of major cardiovascular events, but it did reduce the risk of new or worsening nephropathy. 2 As worsening albuminuria and progressive renal dysfunction are strongly associated with increased risk of major cardiovascular events, endstage renal disease and death in patients with type 2 diabetes, the renal effects may yet prove beneficial for long-term cardiovascular risk. As expected, an increased incidence of hypoglycaemia was observed among patients in the intensive glucose control compared with standard control arms. 2 Overall, the incidence of severe hypoglycaemia was much lower than that reported in other trials of intensive glucose lowering. Using this approach, intensive glucose control was not associated with increased mortality, rather a small, non-significant reduction of 7% in all-cause death. Assuming the adverse mortality effects in ACCORD were not due to chance, there are a number of explanations for the different findings in the three trials. One is that ACCORD, VADT and ADVANCE studied different types of patients (see Table 1 ), and another is that the different approaches taken to intensive glucose control in the three trials led to the differing results. However, post hoc analyses of patient subgroups defined by duration of diabetes and previous history of cardiovascular disease in ADVANCE did not reveal any significant heterogeneity in the treatment effects on-all cause mortality. Another explanation is that ACCORD and VADT used an aggressive strategy with early implementation of a regimen using multiple oral hypoglycaemic agents, as well as insulin, whereas ADVANCE used a more incremental approach with progressive intensification over a much longer time-frame. This is reflected in the high proportion of patients in the intensive glucose control arm of ACCORD who eventually took insulin (77%) and thiazolidinediones (92%), whereas ADVANCE had a slower rate of decline of HbA 1c in the intensive arm, with more than 90% on a sulphonylurea (gliclazide-modified release) but only 40% on insulin and 17% on thiazolidinediones by the end of follow-up. As a consequence, most of the reduction in HbA 1c achieved in the intensive group in ACCORD There were also significant differences in the mean weight gain in these three studies. In the ACCORD and VADT trials, the mean weight gain from baseline was 3.5 and 4kg in those on intensive glucose lowering, respectively, whereas in the ADVANCE trial there was no weight gain among patients in the intensive glucose lowering arm (see Figure 4) . 
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